Uses human-genetics research to find precision drug targets; lead programs target Pompe disease and kidney disease.
Uses human-genetics research to find precision drug targets; lead programs target Pompe disease and kidney disease.
Has no approved medicine, so it lives on money raised from investors and on payments from partners, such as upfront and milestone fees, rather than product sales. Sales would start only if a drug is approved and launched. Its genetics-based list of drug targets is the asset it hopes to turn into several medicines.
Moat: narrow (data, IP / patents). A large genetics/target-discovery data engine underpins its pipeline selection process.
Headquarters: South San Francisco, California, US · Founded: 2019 · Employees: 141
Size Maze Therapeutics (MAZE) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $1.71B, the 1874th largest of 3,085 United States companies the cockpit tracks. Shares closed at $31.20 on 18 Nov 2026.
Performance Over six months the shares gained 27.4%, against +1.7% for the median peer and -2.2% for the United States market (cap-weighted) — 4th highest of 20 in its peer set.
Growth Revenue fell 100.0% over the last twelve months (peer median +13.8%); the operating margin is -820.8% (peer median 9.9%).
Valuation It trades at 68.8× enterprise value to sales against a peer median of 5.1× (most expensive of 20).
Capital Return on invested capital runs 146.5 points below its cost of capital (14.9% WACC).
Short interest Short interest is 12.0% of the free float (30 Oct 2026).
Next results Next results expected around 5 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $20.0M | $0 | $168M | $0 | $0 |
| Revenue growth | — | -100% | — | — | — |
| Gross profit | $18.3M | -$2.40M | $164M | -$4.09M | -$3.82M |
| EBITDA | -$162M | -$140M | $60.9M | -$94.5M | -$107M |
| Net income | -$151M | -$131M | $18.4M | -$100M | -$115M |
| Free cash flow | -$115M | -$113M | $74.8M | -$87.3M | -$101M |
| Capital expenditure | $522,000 | $794,000 | $1.15M | $441,000 | $1.97M |
| Total debt | $59.6M | $23.3M | $26.6M | $49.6M | $32.1M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Maze Therapeutics MAZE | $1.71B | +27% | -100% | -821% | 68.8× | n/a |
| Regeneron Pharmaceuticals REGN | $97.8B | +46% | +19% | 30% | 5.4× | -1.1% |
| Sanofi SAN.PA | $114B | +13% | +15% | 27% | 2.6× | -4.8% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | MAZE | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -3.9% | -0.5% | 8th lowest of 21 |
| 6-month return | +27.4% | +1.7% | 4th highest of 20 |
| Distance from 52-week high | -41.9% | -34.3% | 8th lowest of 21 |
| Revenue growth (TTM) | -100.0% | +13.8% | lowest of 20 |
| Operating margin | -820.8% | 9.9% | lowest of 20 |
| EV / Sales | 68.8× | 5.1× | most expensive of 20 |
| ROIC minus cost of capital | -146.5 pp | -0.8 pp | lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Maze Therapeutics MAZE | United States | $1.71B | +27% | -100% | -821% | 68.8× | n/a | n/a |
| Faes Farma FAE.MC | Spain | $1.71B | +6% | +32% | 14% | 2.6× | 3.7% | +9.9% |
| ApicHope Pharmaceutical 300723.SZ | China | $1.70B | -36% | -28% | -50% | 16.7× | 11.3% | -11.0% |
| BrightGene Bio-Medical Technology 688166.SS | China | $1.71B | -57% | +14% | 7% | 9.7× | 35.3% | +9.2% |
| Caplin Point Laboratories CAPLIPOINT.NS | India | $1.70B | +2% | +17% | 31% | 6.3× | 24.3% | +15.7% |
| Mayinglong Pharmaceutical 600993.SS | China | $1.70B | +2% | +7% | 17% | 2.3× | -3.5% | +6.8% |
| Indegene INDGN.NS | India | $1.69B | +28% | +36% | 12% | 3.6× | 31.4% | +29.4% |
| NATCO Pharma NATCOPHARM.NS | India | $1.73B | -27% | -30% | 17% | 5.1× | 20.5% | +19.0% |
| Zhejiang Wolwo Bio-Pharmaceutical 300357.SZ | China | $1.67B | -12% | +7% | 39% | 8.9× | 18.4% | +10.8% |
| Braveheart Bio BRVE | United States | $1.67B | n/a | n/a | n/a | n/a | n/a | n/a |
| Consun Pharmaceutical 1681.HK | Hong Kong | $1.65B | +8% | +15% | 35% | 2.2× | -14.9% | +13.5% |
| Agios Pharmaceuticals AGIO | United States | $1.78B | +4% | +214% | -298% | 8.3× | n/a | n/a |
| Shenzhen Hepalink Pharmaceutical 9989.HK | Hong Kong | $1.78B | -13% | -1% | 8% | 2.1× | -0.4% | -0.2% |
| Harbin Pharmaceutical 600664.SS | China | $1.78B | +32% | +2% | 5% | 0.7× | -5.3% | +8.2% |
| Eton Pharmaceuticals ETON | United States | $1.79B | +226% | +101% | 29% | 12.4× | 21.9% | +359.6% |
| Tonghua Golden-Horse Pharmaceutical Industry 000766.SZ | China | $1.62B | -47% | -18% | 9% | 12.2× | 33.0% | +0.9% |
| United Laboratories International 3933.HK | Hong Kong | $1.80B | -20% | -13% | 5% | 0.6× | 1.2% | +7.8% |
| AstraZeneca Pharma India ASTRAZEN.NS | India | $1.62B | -30% | +30% | 10% | 5.6× | 42.4% | +23.0% |
| Qingdao Baheal Medical 301015.SZ | China | $1.81B | +2% | -6% | 8% | 2.0× | 10.1% | +5.0% |
| Ultragenyx Pharmaceutical RARE | United States | $1.81B | -24% | +16% | -64% | 3.7× | n/a | n/a |
| Zymeworks ZYME | United States | $1.81B | +5% | +98% | 17% | 8.9× | n/a | n/a |